^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Ovarian Cancer
    Drug:pegylated liposomal doxorubicin (Topoisomerase II inhibitor) +
    Yondelis (trabectedin) (Alkylating agent, DNA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ESMO 2023
    Title:

    770P - Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study

    Published date:
    10/16/2023
    Excerpt:
    For BRCAmut, T+PLD response was CR 28.6%, PR 42.9%, SD 14.3%, PD 14.3%....T+PLD is well tolerated by OC pts with 70 years or older. The adverse reactions are comparable to those published for younger pts and efficacy remains beneficial. Albeit in a small sample, a high overall response rate was observed for BRCAmut pts.